Skip to main content
  • Register
  • Help
  • Contact us
  • Log out of your HL account

Kiniksa Pharmaceuticals Ltd (KNSA) USD0.000273235 A

Sell:$8.86 Buy:$8.87 Change: $0.99 (10.04%)
NASDAQ:3.00%
Market closed |  Prices as at close on 23 August 2019 | Switch to live prices |
Sell:$8.86
Buy:$8.87
Change: $0.99 (10.04%)
Deal now Deal for just £11.95 per trade in a ISA, Lifetime ISA, SIPP or Fund & Share Account
Market closed |  Prices as at close on 23 August 2019 | Switch to live prices |
Sell:$8.86
Buy:$8.87
Change: $0.99 (10.04%)
Market closed |  Prices as at close on 23 August 2019 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a ISA, Lifetime ISA, SIPP or Fund & Share Account
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Kiniksa Pharmaceuticals, Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients suffering from debilitating diseases. The Company’s programs include Rilonacept, which is a protein for inhibiting interleukin-1 alpha and interleukin-1beta; Mavrilimumab, is a monoclonal antibody that antagonizes the signaling of granulocyte macrophage colony stimulating factor, or GM-CSF; KPL-716, is a monoclonal antibody that simultaneously inhibits the signaling of the cytokines interleukin-31, or IL-31, and oncostatin M, or OSM, by targeting their common receptor subunit, oncostatin M receptor beta, or OSMR beta; KPL-045 is a monoclonal antibody inhibitor of the CD30/CD30L interaction, a T-cell co-stimulatory receptor involved in activated T-memory cell function, and KPL-404, is a central control node of T-cell-dependent, B-cell-mediated humoral adaptive immunity.

Contact details

Address:
Clarendon House, 2 Church Street
HAMILTON
HM11
Bermuda
Telephone:
+1 (441) 7814399100
Website:
www.kiniksa.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
KNSA
ISIN:
BMG5269C1010
Market cap:
$568.33 million
Shares in issue:
54.86 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
Bermuda
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Sanjiv Patel
    Chairman of the Board, Chief Executive Officer
  • Stephen Mahoney
    President, Chief Operating Officer
  • Chris Heberlig
    Chief Financial Officer, Executive Vice President, Treasurer
  • Thomas Beetham
    Executive Vice President, Chief Legal Officer and Corporate Development, and Secretary
  • John Paolini
    Senior Vice President and Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.
Deal now Deal for just £11.95 per trade in a ISA, Lifetime ISA, SIPP or Fund & Share Account

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.